Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $35000.0.

  • ImmunityBio's Other Working Capital Changes fell 540.54% to $35000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 13675.71%. This contributed to the annual value of -$5.5 million for FY2024, which is 814.03% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's Other Working Capital Changes is $35000.0, which was down 540.54% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Other Working Capital Changes registered a high of $13.4 million during Q2 2022, and its lowest value of -$9.7 million during Q1 2023.
  • Moreover, its 5-year median value for Other Working Capital Changes was $37000.0 (2024), whereas its average is $275736.8.
  • In the last 5 years, ImmunityBio's Other Working Capital Changes crashed by 102717.7% in 2023 and then skyrocketed by 1132857.14% in 2025.
  • ImmunityBio's Other Working Capital Changes (Quarter) stood at -$517000.0 in 2021, then soared by 513.35% to $2.1 million in 2022, then skyrocketed by 64.01% to $3.5 million in 2023, then crashed by 260.31% to -$5.6 million in 2024, then skyrocketed by 100.62% to $35000.0 in 2025.
  • Its last three reported values are $35000.0 in Q3 2025, $4.0 million for Q2 2025, and $242000.0 during Q1 2025.